In the News: October Regulatory and Development Updates
Camargo
NOVEMBER 11, 2020
The speed of the submission in January 2020 and approval in October 2020 was attributed to the retrospective testing of available tumor tissue samples from patients enrolled in three clinical trials that led to the accelerated approval of larotrectinib.
Let's personalize your content